Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment

Robatel, Steve; Schenk, Mirjam

doi:10.3390/cancers14040985

Cited by 37 publications

(30 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies suggested that the low count of dendric cells in the pancreatic tumour environment is the reason behind the low response to immunotherapy [ 53 ]. Although Pembrolizumab was approved by the FDA as an anti-programmed death-1 (PD-1) inhibitor for advanced PDAC, unfortunately, its effectiveness is limited to less than 1% of patients [ 64 , 65 , 66 ].…”

Section: Overview Of Pancreatic Cancermentioning

confidence: 99%

Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies

Bazeed

Day

Garg

2022

Cancers

View full text Add to dashboard Cite

Pancreatic cancer (PC) remains the seventh leading cause of cancer-related deaths worldwide and the third in the United States, making it one of the most lethal solid malignancies. Unfortunately, the symptoms of this disease are not very apparent despite an increasing incidence rate. Therefore, at the time of diagnosis, 45% of patients have already developed metastatic tumours. Due to the aggressive nature of the pancreatic tumours, local interventions are required in addition to first-line treatments. Locoregional interventions affect a specific area of the pancreas to minimize local tumour recurrence and reduce the side effects on surrounding healthy tissues. However, compared to the number of new studies on systemic therapy, very little research has been conducted on localised interventions for PC. To address this unbalanced focus and to shed light on the tremendous potentials of locoregional therapies, this work will provide a detailed discussion of various localised treatment strategies. Most importantly, to the best of our knowledge, the aspect of localised drug delivery systems used in PC was unprecedentedly discussed in this work. This review is meant for researchers and clinicians considering utilizing local therapy for the effective treatment of PC, providing a thorough guide on recent advancements in research and clinical trials toward locoregional interventions, together with the authors’ insight into their potential improvements.

show abstract

Section: Overview Of Pancreatic Cancermentioning

confidence: 99%

Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies

Bazeed

Day

Garg

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The viability of isolated cancer tissue samples is relatively low, largely due to local environmental factors. Moreover, various treatments such as neoadjuvant chemo- or radio-therapy have an impact on cell viability [ 2 ]. Successful scRNA-seq requires removal of dead cells [ 3 ] and debris, so isolation of as many live cells as possible from the initial sample is beneficial [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

An Innovative Approach to Tissue Processing and Cell Sorting of Fixed Cells for Subsequent Single-Cell RNA Sequencing

Mutisheva

Robatel

Bäriswyl

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

Although single-cell RNA sequencing (scRNA-seq) is currently the gold standard for the analysis of cell-specific expression profiles, the options for processing, staining, and preserving fresh cells remain very limited. Immediate and correct tissue processing is a critical determinant of scRNA-seq success. One major limitation is the restricted compatibility of fixation approaches, which must not destabilize or alter antibody labeling or RNA content or interfere with cell integrity. An additional limitation is the availability of expensive, high-demand cell-sorting equipment to exclude debris and dead or unwanted cells before proceeding with sample sequencing. The goal of this study was to develop a method that allows cells to be fixed and stored prior to FACS sorting for scRNA-seq without compromising the quality of the results. Finally, the challenge of preserving as many living cells as possible during tissue processing is another crucial issue addressed in this study. Our study focused on pancreatic ductal adenocarcinoma samples, where the number of live cells is rather limited, as in many other tumor tissues. Harsh tissue dissociation methods and sample preparation for analysis can negatively affect cell viability. Using the murine pancreatic cancer model Pan02, we evaluated the semi-automated mechanical/enzymatic digestion of solid tumors by gentleMACS Dissociator and compared it with mechanical dissociation of the same tissue. Moreover, we investigated a type of cell fixation that is successful in preserving cell RNA integrity yet compatible with FACS and subsequent scRNA-sequencing. Our protocol allows tissue to be dissociated and stained in one day and proceeds to cell sorting and scRNA-seq later, which is a great advantage for processing clinical patient material.

show abstract

“…However, the International Association of Pancreatology (IAP) introduced the ABC criteria that determine the resectability, not only on the localization regarding the blood vessels but also by incorporating the ECOG status, the lymph node status, as well as tumor markers. This underlines the complexity of determining valid protocols for the resectability of PDAC [ 3 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

3D In Vivo Models for Translational Research on Pancreatic Cancer: The Chorioallantoic Membrane (CAM) Model

Pion

Karnosky

Boscheck

et al. 2022

Cancers

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with adverse outcomes that have barely improved over the last decade. About half of all patients present with metastasis at the time of diagnosis, and the 5-year overall survival rate across all stages is only 6%. Innovative in vivo research models are necessary to combat this cancer and to discover novel treatment strategies. The chorioallantoic membrane (CAM) model represents one 3D in vivo methodology that has been used in a large number of studies on different cancer types for over a century. This model is based on a membrane formed within fertilized chicken eggs that contain a dense network of blood vessels. Because of its high cost-efficiency, simplicity, and versatility, the CAM model appears to be a highly valuable research tool in the pursuit of gaining more in-depth insights into PDAC. A summary of the current literature on the usage of the CAM model for the investigation of PDAC was conducted and subdivided into angiogenesis, drug testing, modifications, personalized medicine, and further developments. On this comprehensive basis, further research should be conducted on PDAC in order to improve the abysmal prognosis of this malignant disease.

show abstract

Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment

Cited by 37 publications

References 161 publications

Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies

Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies

An Innovative Approach to Tissue Processing and Cell Sorting of Fixed Cells for Subsequent Single-Cell RNA Sequencing

3D In Vivo Models for Translational Research on Pancreatic Cancer: The Chorioallantoic Membrane (CAM) Model

Contact Info

Product

Resources

About